Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients

May Abd Al Samid, Belal Chaudhary, Yazan S. Khaled, Basil J. Ammori, Eyad Elkord

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Regulatory T cells (Tregs) comprise numerous heterogeneous subsets with distinct phenotypic and functional features. Identifying Treg markers is critical to investigate the role and clinical impact of various Treg subsets in pathological settings, and also for developing more effective immunotherapies. We have recently shown that non-activated FoxP3-Helios+ and activated FoxP3+/-Helios+ CD4+ T cells express GARP/LAP immunosuppressive markers in healthy donors. In this study we report similar observations in the peripheral blood of patients with pancreatic cancer (PC) and liver metastases from colorectal cancer (LICRC). Comparing levels of different Treg subpopulations in cancer patients and controls, we report that in PC patients, and unlike LICRC patients, there was no increase in Treg levels as defined by FoxP3 and Helios. However, defining Tregs based on GARP/LAP expression showed that FoxP3-LAP+ Tregs in non-activated and activated settings, and FoxP3+Helios+GARP+LAP+ activated Tregs were significantly increased in both groups of patients, compared with controls. This work implies that a combination of Treg-specific markers could be used to more accurately determine expanded Treg subsets and to understand their contribution in cancer settings. Additionally, GARP-/+LAP+ CD4+ T cells made IL-10, and not IFN-γ, and levels of IL-10-secreting CD4+ T cells were elevated in LICRC patients, especially with higher tumor staging. Taken together, our results indicate that investigations of Treg levels in different cancers should consider diverse Treg-related markers such as GARP, LAP, Helios, and others and not only FoxP3 as a sole Treg-specific marker.

Original languageEnglish
Pages (from-to)14083-14094
Number of pages12
JournalOncotarget
Volume7
Issue number12
DOIs
Publication statusPublished - 22 Mar 2016
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Neoplasms
Neoplasm Metastasis
T-Lymphocytes
Pancreatic Neoplasms
Interleukin-10
Neoplasm Staging
Liver
Regulatory T-Lymphocytes
Liver Neoplasms
Immunosuppressive Agents
Immunotherapy
Tissue Donors

Keywords

  • FoxP3
  • GARP/LAP
  • Helios
  • Markers
  • Regulatory T cells

ASJC Scopus subject areas

  • Oncology

Cite this

Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients. / Abd Al Samid, May; Chaudhary, Belal; Khaled, Yazan S.; Ammori, Basil J.; Elkord, Eyad.

In: Oncotarget, Vol. 7, No. 12, 22.03.2016, p. 14083-14094.

Research output: Contribution to journalArticle

Abd Al Samid, May ; Chaudhary, Belal ; Khaled, Yazan S. ; Ammori, Basil J. ; Elkord, Eyad. / Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients. In: Oncotarget. 2016 ; Vol. 7, No. 12. pp. 14083-14094.
@article{c68c386ba283480dbdde403cc2bf7811,
title = "Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients",
abstract = "Regulatory T cells (Tregs) comprise numerous heterogeneous subsets with distinct phenotypic and functional features. Identifying Treg markers is critical to investigate the role and clinical impact of various Treg subsets in pathological settings, and also for developing more effective immunotherapies. We have recently shown that non-activated FoxP3-Helios+ and activated FoxP3+/-Helios+ CD4+ T cells express GARP/LAP immunosuppressive markers in healthy donors. In this study we report similar observations in the peripheral blood of patients with pancreatic cancer (PC) and liver metastases from colorectal cancer (LICRC). Comparing levels of different Treg subpopulations in cancer patients and controls, we report that in PC patients, and unlike LICRC patients, there was no increase in Treg levels as defined by FoxP3 and Helios. However, defining Tregs based on GARP/LAP expression showed that FoxP3-LAP+ Tregs in non-activated and activated settings, and FoxP3+Helios+GARP+LAP+ activated Tregs were significantly increased in both groups of patients, compared with controls. This work implies that a combination of Treg-specific markers could be used to more accurately determine expanded Treg subsets and to understand their contribution in cancer settings. Additionally, GARP-/+LAP+ CD4+ T cells made IL-10, and not IFN-γ, and levels of IL-10-secreting CD4+ T cells were elevated in LICRC patients, especially with higher tumor staging. Taken together, our results indicate that investigations of Treg levels in different cancers should consider diverse Treg-related markers such as GARP, LAP, Helios, and others and not only FoxP3 as a sole Treg-specific marker.",
keywords = "FoxP3, GARP/LAP, Helios, Markers, Regulatory T cells",
author = "{Abd Al Samid}, May and Belal Chaudhary and Khaled, {Yazan S.} and Ammori, {Basil J.} and Eyad Elkord",
year = "2016",
month = "3",
day = "22",
doi = "10.18632/oncotarget.7334",
language = "English",
volume = "7",
pages = "14083--14094",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "12",

}

TY - JOUR

T1 - Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients

AU - Abd Al Samid, May

AU - Chaudhary, Belal

AU - Khaled, Yazan S.

AU - Ammori, Basil J.

AU - Elkord, Eyad

PY - 2016/3/22

Y1 - 2016/3/22

N2 - Regulatory T cells (Tregs) comprise numerous heterogeneous subsets with distinct phenotypic and functional features. Identifying Treg markers is critical to investigate the role and clinical impact of various Treg subsets in pathological settings, and also for developing more effective immunotherapies. We have recently shown that non-activated FoxP3-Helios+ and activated FoxP3+/-Helios+ CD4+ T cells express GARP/LAP immunosuppressive markers in healthy donors. In this study we report similar observations in the peripheral blood of patients with pancreatic cancer (PC) and liver metastases from colorectal cancer (LICRC). Comparing levels of different Treg subpopulations in cancer patients and controls, we report that in PC patients, and unlike LICRC patients, there was no increase in Treg levels as defined by FoxP3 and Helios. However, defining Tregs based on GARP/LAP expression showed that FoxP3-LAP+ Tregs in non-activated and activated settings, and FoxP3+Helios+GARP+LAP+ activated Tregs were significantly increased in both groups of patients, compared with controls. This work implies that a combination of Treg-specific markers could be used to more accurately determine expanded Treg subsets and to understand their contribution in cancer settings. Additionally, GARP-/+LAP+ CD4+ T cells made IL-10, and not IFN-γ, and levels of IL-10-secreting CD4+ T cells were elevated in LICRC patients, especially with higher tumor staging. Taken together, our results indicate that investigations of Treg levels in different cancers should consider diverse Treg-related markers such as GARP, LAP, Helios, and others and not only FoxP3 as a sole Treg-specific marker.

AB - Regulatory T cells (Tregs) comprise numerous heterogeneous subsets with distinct phenotypic and functional features. Identifying Treg markers is critical to investigate the role and clinical impact of various Treg subsets in pathological settings, and also for developing more effective immunotherapies. We have recently shown that non-activated FoxP3-Helios+ and activated FoxP3+/-Helios+ CD4+ T cells express GARP/LAP immunosuppressive markers in healthy donors. In this study we report similar observations in the peripheral blood of patients with pancreatic cancer (PC) and liver metastases from colorectal cancer (LICRC). Comparing levels of different Treg subpopulations in cancer patients and controls, we report that in PC patients, and unlike LICRC patients, there was no increase in Treg levels as defined by FoxP3 and Helios. However, defining Tregs based on GARP/LAP expression showed that FoxP3-LAP+ Tregs in non-activated and activated settings, and FoxP3+Helios+GARP+LAP+ activated Tregs were significantly increased in both groups of patients, compared with controls. This work implies that a combination of Treg-specific markers could be used to more accurately determine expanded Treg subsets and to understand their contribution in cancer settings. Additionally, GARP-/+LAP+ CD4+ T cells made IL-10, and not IFN-γ, and levels of IL-10-secreting CD4+ T cells were elevated in LICRC patients, especially with higher tumor staging. Taken together, our results indicate that investigations of Treg levels in different cancers should consider diverse Treg-related markers such as GARP, LAP, Helios, and others and not only FoxP3 as a sole Treg-specific marker.

KW - FoxP3

KW - GARP/LAP

KW - Helios

KW - Markers

KW - Regulatory T cells

UR - http://www.scopus.com/inward/record.url?scp=84971667607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971667607&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7334

DO - 10.18632/oncotarget.7334

M3 - Article

C2 - 26885615

AN - SCOPUS:84971667607

VL - 7

SP - 14083

EP - 14094

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 12

ER -